David Grinblatt
Distinguished in Richter Syndrome

Dr. David Grinblatt

Hematology | Oncology
Endeavor Health
Endeavor Health Medical Group
2650 Ridge Ave., Kellogg Cancer Center, 
Evanston, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Distinguished in Richter Syndrome
Endeavor Health
Endeavor Health Medical Group
2650 Ridge Ave., Kellogg Cancer Center, 
Evanston, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Grinblatt, MD, a hematologist at Endeavor Health Cancer Institute, specializes in diagnosing and treating blood disorders using the most advanced and effective therapies available. He is actively involved in bringing CAR-T cell therapy to patients, reflecting his commitment to innovation and personalized care. Dr. Grinblatt values optimism and clear communication and works closely with patients to develop treatment plans that align with their unique situation and diagnosis.

Dr. Grinblatt is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Case Western Reserve University, 1986
Residency
Rush-Presbyterian-St Luke's Medical Center, Internal Medicine, 1989
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine
Fellowships
McGaw Medical Center of Northwestern University, Hematology/Oncology, 1992
Hospital Affiliations
Swedish Hospital
Northshore University Healthsystem - Evanston Hospital
Languages Spoken
English
Hebrew
Yiddish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 15 Less Insurance Carriers -

Locations

Endeavor Health Medical Group
2650 Ridge Ave., Kellogg Cancer Center, Evanston, IL 60201
Call: 847-570-2112
Other Locations
Endeavor Health Medical Group
2180 Pfingsten Rd., Kellogg Cancer Center, Glenview, IL 60026
Call: 847-503-1000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Mesna, Methotrexate, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
Enrollment Status: Completed
Publish Date: December 01, 2021
Intervention Type: Drug, Radiation
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
Study Phase: Phase 2
View 5 Less Clinical Trials

23 Total Publications

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.
Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.
Journal: HemaSphere
Published: March 21, 2025
View All 23 Publications
Similar Doctors
Distinguished in Richter Syndrome
Dr. Shuo Ma
Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Shuo Ma
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (10.8 miles away)
866-587-4322
Experience:
32+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shuo Ma is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Ma has been practicing medicine for over 32 years and is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration.

Lynne Kaminer
Distinguished in Richter Syndrome
Dr. Lynne Kaminer
Hematology | Oncology
Distinguished in Richter Syndrome
Dr. Lynne Kaminer
Hematology | Oncology

Endeavor Health Medical Group

2650 Ridge Ave., Kellogg Cancer Center, 
Evanston, IL 
 (1.7 miles away)
847-570-2112
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lynne Susan Kaminer, MD, a hematologist at Endeavor Health, provides care for patients with blood cancers and disorders. She manages complex conditions such as leukemia, lymphoma, myeloma and anemia. Dr. Kaminer uses a multidisciplinary approach to develop individualized treatment plans for both malignant and non-malignant hematologic diseases. Dr. Kaminer is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Distinguished in Richter Syndrome
Dr. Nadia Khan
Hematology | Oncology | Transplant Surgery
Distinguished in Richter Syndrome
Dr. Nadia Khan
Hematology | Oncology | Transplant Surgery
1520 W Harrison St, 
Chicago, IL 
 (11.7 miles away)
800-226-2371
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nadia Khan is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Khan is rated as a Distinguished provider by MediFind in the treatment of Richter Syndrome. Her top areas of expertise are Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL). Dr. Khan is currently accepting new patients.

VIEW MORE RICHTER SYNDROME DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grinblatt's expertise for a condition
ConditionClose
  • Elite
  • Chronic Lymphocytic Leukemia (CLL)
    Dr. Grinblatt is
    Elite
    . Learn about Chronic Lymphocytic Leukemia (CLL).
    See more Chronic Lymphocytic Leukemia (CLL) experts
  • Distinguished
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Grinblatt is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Grinblatt is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Grinblatt is
    Distinguished
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Adult Immune Thrombocytopenia
    Dr. Grinblatt is
    Distinguished
    . Learn about Adult Immune Thrombocytopenia.
    See more Adult Immune Thrombocytopenia experts
  • B-Cell Lymphoma
    Dr. Grinblatt is
    Distinguished
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Childhood Acute Myeloid Leukemia
    Dr. Grinblatt is
    Distinguished
    . Learn about Childhood Acute Myeloid Leukemia.
    See more Childhood Acute Myeloid Leukemia experts
View All 26 Distinguished Conditions
  • Advanced
  • Acute Erythroid Leukemia (AEL)
    Dr. Grinblatt is
    Advanced
    . Learn about Acute Erythroid Leukemia (AEL).
    See more Acute Erythroid Leukemia (AEL) experts
  • Acute Monoblastic Leukemia (AmoL)
    Dr. Grinblatt is
    Advanced
    . Learn about Acute Monoblastic Leukemia (AmoL).
    See more Acute Monoblastic Leukemia (AmoL) experts
  • Acute Promyelocytic Leukemia
    Dr. Grinblatt is
    Advanced
    . Learn about Acute Promyelocytic Leukemia.
    See more Acute Promyelocytic Leukemia experts
  • Agranulocytosis
    Dr. Grinblatt is
    Advanced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Anaplastic Large Cell Lymphoma
    Dr. Grinblatt is
    Advanced
    . Learn about Anaplastic Large Cell Lymphoma.
    See more Anaplastic Large Cell Lymphoma experts
  • Anemia
    Dr. Grinblatt is
    Advanced
    . Learn about Anemia.
    See more Anemia experts
View All 29 Advanced Conditions
  • Experienced
  • Acquired Agranulocytosis
    Dr. Grinblatt is
    Experienced
    . Learn about Acquired Agranulocytosis.
    See more Acquired Agranulocytosis experts
  • Acute Eosinophilic Pneumonia
    Dr. Grinblatt is
    Experienced
    . Learn about Acute Eosinophilic Pneumonia.
    See more Acute Eosinophilic Pneumonia experts
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Grinblatt is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Myelomonocytic Leukemia
    Dr. Grinblatt is
    Experienced
    . Learn about Acute Myelomonocytic Leukemia.
    See more Acute Myelomonocytic Leukemia experts
  • Aleukemic Leukemia Cutis (ALC)
    Dr. Grinblatt is
    Experienced
    . Learn about Aleukemic Leukemia Cutis (ALC).
    See more Aleukemic Leukemia Cutis (ALC) experts
  • Alpha Thalassemia
    Dr. Grinblatt is
    Experienced
    . Learn about Alpha Thalassemia.
    See more Alpha Thalassemia experts
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.